Skip to main content
. 2022 Sep 9;13:975246. doi: 10.3389/fimmu.2022.975246

Figure 5.

Figure 5

Kaplan-Meier estimates of progression-free survival (PFS) (A) and overall survival (OS) (B) in patients with EGFR exon 19 deletion (19del) or EGFR L858R mutation.